Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced its entry into a definitive agreement to acquire Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company headquartered in London, UK, focused on pioneering the design and development of siRNA (short interfering RNA) therapies in areas of high unmet need.

The purchase price of $20 per ADS in cash, with each ADS representing three ordinary shares of Silence Therapeutics (or $6.6667 per ordinary share), represents an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion. The consideration represents an 82% premium to Silence Therapeutics’ 30-day volume-weighted average price of $10.99, as of the close of trading on October 16, 2026, the last trading day prior to the transaction announcement. The transaction is subject to satisfaction of customary closing conditions.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.